Table 2

 Demographic and clinical characteristics of the population used for the analysis of the 28 joint disease activity score response

Characteristic
Values are per cent, n, or mean (SD) as indicated.
*At least one active prescription at the point of sampling (low dose (<100 mg daily) salicylates not included).
DAS28, 28 joint disease activity score; DMARD, disease modifying antirheumatic drug; NSAID, non-steroidal anti-inflammatory drug; y, years.
Number of patients25
Age (y)68 (13)
Female72%
Period since diagnosis of rheumatoid arthritis (y)8 (7)
Rheumatoid factor positive60%
DAS28 at baseline5.1 (0.9)
DAS28 >5.1 at baseline (n)13
DAS28 >3.2 and ⩽5.1 at baseline (n)12
Leflunomide prescribed as first DMARD24%
Concomitant corticosteroid use40%
Concomitant other DMARD use0%
Concomitant NSAID use*38%